What is Exenatide?
Exenatide was one of the earlier GLP-1 receptor agonists. Product formulation matters: immediate-release and prolonged-release versions have different schedules and device instructions.
Approved-use context
Exenatide products are authorised for type 2 diabetes in defined circumstances, including use with specified glucose-lowering medicines. They are not authorised as interchangeable products.
How it works
Exenatide activates GLP-1 receptors, supporting glucose-dependent insulin release, reducing glucagon secretion and slowing gastric emptying.
Formulations and schedules
Products include shorter-acting injection pens and prolonged-release weekly formulations. A user must identify the exact brand and formulation rather than relying on the ingredient name alone.
Useful information to track
- Exact product and formulation
- Administration date and time
- Blood-glucose information requested by a clinician
- Digestive symptoms
- Renal monitoring or review dates when requested
Important safety considerations
- Nausea and other gastrointestinal effects are common
- Renal function can be clinically relevant, especially with dehydration
- Persistent severe abdominal pain needs urgent clinical advice
- Hypoglycaemia risk can increase with sulfonylureas or insulin
- Each device has its own preparation and missed-dose instructions
Questions for a clinician or pharmacist
- Which exenatide formulation am I using?
- How does kidney function affect treatment decisions?
- What should be recorded alongside glucose readings?
- Which device instructions apply to my product?
Authoritative references
Regulatory status, warnings and availability can change. Check the current official product information for your country.